Open access
Prospective Evaluation of Quality‐of‐Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION‐HF 12‐Month Results
V. Potoupni
A. Boulmpou
S. Maragkoudakis
A. Briasoulis
E. Foukarakis
A. Stavrati
Konstantinos Papadopoulos
Katerina K. Naka
Anna Kotsia
I. Parissis
A. Ziakas
S. Adamopoulos
Dimitrios N. Tziakas
S. Patsilinakos
Melanie Konstantinidou
P. Davlouros
Zacharias Christogiannis
Konstantinos Tsitlakidis
Ioannis Pantelakis
G. Stefanakis
M. Kolios
Ioannis Baltogiannis
Evangelos Voltyrakis
C. Varounis
A. Samothrakitis
Dimitrios Krikidis
Panagiotis Tsialoukis
Zoe Paparepa
D. Gourlis
N. Papoutsidakis
A. Karavidas
C. Papadopoulos
Medicine
Abstract
Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction ≤ 40%, remains a major global health challenge, associated with substantial morbidity, mortality, and impaired quality of life (QoL), particularly in patients with higher NYHA class. Sodium–glucose cotransporter‐2 (SGLT2) inhibitors have emerged as a cornerstone therapy for HFrEF, significantly reducing hospitalizations and mortality regardless of glycemic status, sex, race, or comorbidities.